The Dutch organization Kansen voor West (Opportunities for the West) has awarded a subsidy of 6.8 million euros to the Advancing Nuclear Medicine consortium to develop new radiopharmaceuticals to advance nuclear medicine.
The initiative is known as Field-Lab and is led by the Nuclear Research and Consultancy Group (NRG), which operates the High Flux Reactor in Petten, the Netherlands, according to a 18 January report in World Nuclear News. Field-Lab will be based at the Energy and Health campus next to the reactor, which is one of the world's major suppliers of molybdenum-99 (Mo-99), the precursor to technetium-99m.
NRG's seven partners in the Advancing Nuclear Medicine consortium are the Netherlands Cancer Institute -- Antoni van Leeuwenhoek, Stichting Voorbereiding Pallas, Radboud University Medical Center, Erasmus University Medical Center, VU University Medical Center Amsterdam, NucMed, and FutureChemistry. It also has the support of 15 international organizations, including the German Cancer Research Center and BTG, a Canadian pharmaceutical company.
